13A-1100428
TW I844080、US pending
Amyotrophic lateral sclerosis (ALS) is an age-dependent neurodegenerative disease, which mainly affects the nervous system in the spinal cord. Currently, there is no effective treatment/drug for ALS. Notably, many central nervous degenerative diseases including ALS are closely associated with aging and affected immune system. Our laboratory has previously generated a healthy longevity/anti-cancer mouse model, Eklf (K74R), with single amino substitution, KR, at the conserved sumoylation site (K74) of the mouse hematopoietic/ blood transcription factor EKLF. We have found that upon bone marrow transplantation (BMT) of bone marrow mononuclear cells (BMMNC) containing the hematopoietic stem/ progenitor cells (HSPC) from the Eklf (K74R) mice, wild-type mice would gain anti-cancer ability. Since Eklf ( K74R) mice also showed better exercise behavior and learning memory than the wild-type mice, we have carried two sets of experiments to test whether the Eklf (K74R) gene or blood could rescue the ALS-like pathogenesis in mice: (1) BMT from Eklf (K74R) mice to WT mice; (2) genetic cross of the Eklf (K74R) mice with the ALS mouse model (TDP-43(N390D/+). Our positive results from these experiments have uncovered novel approach/ reagent invaluable for new development of effective ALS therapy in near future.
Bone marrow mononuclear cell transplantation of a novel patented blood system, the rescue effect of which is greater than the wild type blood.
Neurodegenerative disease therapy using a novel gene and blood system
C.-K. James Shen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Novel Therapeutics for Neurodegenerative Disease -ALS (Amyotrophic lateral sclerosis)